Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Cancer Research|July 5, 2006
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironmentYu-Tzu Tai, Xian-Feng Li, Iris Breitkreutz, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Cancers|February 11, 2023
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)Magdalena A Benda, Hanno Ulmer, Roman Weger, et al.
Blood|July 10, 2009
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significanceSimona Blotta, Pierfrancesco Tassone, Rao H Prabhala, et al.
The Journal of Biological Chemistry|December 17, 2002
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cellsKlaus Podar, Yu-Tzu Tai, Craig E Cole, et al.
British Journal of Haematology|July 19, 2006
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomibReshma Shringarpure, Laurence Catley, Deepak Bhole, et al.
Breast Cancer Research : BCR|April 2, 2024
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Breast Cancer Research : BCR|February 28, 2016
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Cancer Research|July 5, 2006
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironmentYu-Tzu Tai, Xian-Feng Li, Iris Breitkreutz, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Cancers|February 11, 2023
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)Magdalena A Benda, Hanno Ulmer, Roman Weger, et al.
Blood|July 10, 2009
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significanceSimona Blotta, Pierfrancesco Tassone, Rao H Prabhala, et al.
The Journal of Biological Chemistry|December 17, 2002
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cellsKlaus Podar, Yu-Tzu Tai, Craig E Cole, et al.
British Journal of Haematology|July 19, 2006
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomibReshma Shringarpure, Laurence Catley, Deepak Bhole, et al.
Breast Cancer Research : BCR|April 2, 2024
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Breast Cancer Research : BCR|February 28, 2016
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
Blood|December 3, 2003
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironmentKlaus Podar, Laurence P Catley, Yu-Tzu Tai, et al.
Pageof 15